SWEDISH ORPHAN/S (SWTUY) Stock Price, News & Analysis

Company Overview

Swedish Orphan Biovitrum AB (publ), trading on the OTC market as SWTUY, is a global biopharmaceutical company focused on the development, manufacturing and commercialization of treatments for rare diseases and other specialty conditions. The company’s core expertise lies in delivering precision therapies in the areas of hemophilia, hereditary and metabolic diseases, immune system disorders and oncology. With a strong research and development pipeline, Swedish Orphan/S seeks to address unmet medical needs through both internally discovered products and strategic partnerships.

Since its formation in 2001 through the consolidation of Swedish Orphan and Biovitrum, the company has established a robust presence across Europe, North America and selected emerging markets. Its portfolio includes a range of protein-based therapies, enzyme replacement treatments and recombinant products. Notable offerings have included long-acting coagulation factors for hemophilia A and B, treatments for lysosomal storage disorders and proprietary antibody therapies in immunology.

Swedish Orphan/S operates an integrated manufacturing network in Scandinavia and collaborates with contract manufacturers to ensure global supply continuity. The company maintains its headquarters in Stockholm, Sweden, and has commercial offices in major markets such as the United States, Germany, France and Japan. This geographic footprint is supported by specialized distribution channels and patient support services designed to navigate the unique challenges of rare-disease treatment access.

Under the leadership of CEO Guido Oelkers and a management team drawn from both the biotech and pharmaceutical industries, Swedish Orphan/S has emphasized sustainable growth and innovation. The company’s research efforts are complemented by academic collaborations and licensing agreements that expand its scientific reach. With a commitment to patients, the organization continues to advance clinical trials, strengthen its product range and explore new therapeutic modalities in precision medicine.

Key Stats

• Today's Range: $24.38 to $24.38
• 50-Day Range: $24.38 to $24.38
• 52-Week Range: $18.50 to $31.96
• Volume: 200 shs
• Average Volume: 1,665 shs
• Market Capitalization: $6.64 billion
• P/E Ratio: 48.76
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

SWTUY Stock Analysis - Frequently Asked Questions

How have SWTUY shares performed this year?

SWEDISH ORPHAN/S's stock was trading at $24.38 on January 1st, 2025. Since then, SWTUY shares have increased by 0.0% and is now trading at $24.38.

How do I buy shares of SWEDISH ORPHAN/S?

Shares of SWTUY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Private Households
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:SWTUY
• Previous Symbol: NASDAQ:SWTUY
• CIK: N/A
• Web: www.sobi.com
• Phone: 46-0-869-720-00
• Fax: N/A
• Employees: 902
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): $0.50
• Trailing P/E Ratio: 48.76
• Forward P/E Ratio: N/A
• P/E Growth: 1.3
• Net Income: $134.73 million
• Net Margins: 25.75%
• Pretax Margin: N/A
• Return on Equity: 29.63%
• Return on Assets: 18.74%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $763.19 million
• Price / Sales: 8.71
• Cash Flow: $0.70 per share
• Price / Cash Flow: 34.66
• Book Value: $2.88 per share
• Price / Book: 8.47

Miscellaneous

• Outstanding Shares: 272,508,000
• Free Float: N/A
• Market Cap: $6.64 billion
• Optionable: Not Optionable
• Beta: 1.81